Core Viewpoint - Iron Mountain (IRM) is expected to report significant growth in quarterly earnings and revenues, with earnings per share projected at $1.19, a 183.3% increase year-over-year, and revenues forecasted at $1.68 billion, reflecting a 9.3% increase compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate for the quarter has remained unchanged over the past 30 days, indicating analysts have not revised their projections [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts estimate 'Revenues- Storage Rental Revenue' to be $990.44 million, indicating a year-over-year increase of 7.7% [4]. - 'Revenues- Service Revenue' is expected to reach $685.41 million, reflecting an 11.5% increase from the same quarter last year [5]. - The 'Global Data Center Business- Total Revenues' is projected at $189.73 million, a 24.3% year-over-year increase, while 'Global Data Center Business- Storage Rental' is expected to be $187.35 million, showing a 27.1% increase [5]. - 'Global Data Center Business- Service' is forecasted to decline to $3.52 million, a decrease of 33.7% year-over-year [5]. Additional Revenue Insights - 'Corporate and Other- Total Revenues' is estimated at $174.64 million, suggesting a 33.2% increase year-over-year [6]. - 'Global RIM Business- Service' is projected to reach $522.28 million, reflecting a 5.7% increase from the previous year [6]. - 'Global RIM Business- Total Revenue' is expected to be $1.32 billion, indicating a 5.6% increase year-over-year [6]. - 'Corporate and Other- Service' is estimated at $159.30 million, a 38.4% increase from the prior year [7]. - 'Global RIM Business- Storage Rental' is projected to be $798.52 million, reflecting a 5.6% increase year-over-year [7]. - 'Corporate and Other- Storage Rental' is expected to reach $17.18 million, indicating a 7.4% increase from the previous year [8]. EBITDA Projections - The 'Global Data Center Business- Adjusted EBITDA' is projected to be $94.15 million, compared to $66.02 million reported in the same quarter last year [8]. Stock Performance - Over the past month, Iron Mountain shares have decreased by 3.3%, while the Zacks S&P 500 composite has increased by 2.3%. The company holds a Zacks Rank 2 (Buy), suggesting it is likely to outperform the overall market in the upcoming period [8].

Company Overview - Genius Sports Limited (GENI) shares increased by 10.6% to $11.25 in the last trading session, with a higher-than-average trading volume, contrasting with a 0.7% gain over the past four weeks [1] - The company is experiencing growth due to expanding partnerships, innovative product launches such as BetVision and SAOT, and the integration of GeniusIQ technology across sports ecosystems [1] Earnings Expectations - Genius Sports is projected to report quarterly earnings of $0.00 per share, reflecting a year-over-year change of +100% [2] - Expected revenues are $118.04 million, which is a 23.7% increase from the same quarter last year [2] Earnings Estimate Revisions - The consensus EPS estimate for Genius Sports has been revised 145.2% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [3] - The stock currently holds a Zacks Rank of 2 (Buy), suggesting favorable market sentiment [3] Industry Comparison - Genius Sports is part of the Zacks Internet - Content industry, where Yelp (YELP) also operates, closing 0.6% higher at $34.9, but has seen a -1.4% return over the past month [3] - Yelp's consensus EPS estimate remains unchanged at $0.48, representing an -11.1% change compared to the previous year, and it also holds a Zacks Rank of 2 (Buy) [4]

Core Viewpoint - Amgen is expected to report quarterly earnings of $5.25 per share, reflecting a 5.6% increase year-over-year, with revenues forecasted at $8.86 billion, also representing a 5.6% year-over-year increase [1]. Earnings Estimates - Over the past 30 days, the consensus EPS estimate has been adjusted downward by 0.2%, indicating a reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong relationship between earnings estimate revisions and short-term stock performance [3]. Revenue and Product Sales Estimates - The consensus estimate for 'Revenue- Product sales' is $8.49 billion, indicating a year-over-year change of +5.6% [5]. - Analysts project 'Product Sales- Neulasta- Total' to reach $92.14 million, reflecting a -12.3% change from the previous year [5]. - 'Product Sales- LUMAKRAS/LUMYKRAS- Total' is expected to be $91.20 million, showing a +7.3% year-over-year change [5]. - 'Product Sales- Otezla- Total' is estimated at $533.54 million, indicating a -1.9% change year-over-year [6]. - 'Product Sales- Neulasta- ROW' is projected at $23.31 million, reflecting a -22.3% change year-over-year [6]. - 'Product Sales- Neulasta- U.S.' is expected to be $66.88 million, indicating a -10.8% change from the prior year [6]. - 'Product Sales- Vectibix- ROW' is estimated at $135.60 million, showing a -1% change from the previous year [7]. - 'Product Sales- Vectibix- U.S.' is forecasted to reach $141.96 million, reflecting a +6.7% year-over-year change [7]. - 'Product Sales- Enbrel- U.S.' is expected to be $786.00 million, indicating a -12.9% change from the prior year [7]. - 'Product Sales- Enbrel- ROW' is projected at $7.01 million, reflecting a +0.1% change year-over-year [8]. - 'Product Sales- Aranesp- ROW' is estimated at $251.00 million, indicating a -2.3% change year-over-year [8]. - 'Product Sales- Aranesp- U.S.' is expected to be $80.25 million, reflecting a -11.8% change from the previous year [8]. Stock Performance - Over the past month, Amgen shares have recorded a return of +1.5%, compared to the Zacks S&P 500 composite's +2.7% change [9].

Core Insights - Imperial Oil (IMO) is expected to report quarterly earnings of $1.22 per share, a decline of 20.8% year-over-year, with revenues projected at $10.54 billion, reflecting a 7.8% increase compared to the previous year [1] Earnings Estimates - The consensus EPS estimate has been revised 1.4% higher over the last 30 days, indicating a collective reevaluation by analysts [2] - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock price performance [3] Key Metrics Projections - Analysts estimate 'Gross Oil - Equivalent Production' to reach 416 thousand barrels, up from 404 thousand barrels year-over-year [5] - 'Gross Natural Gas Production' is forecasted at 29.59 thousand cubic feet, slightly down from 30.00 thousand cubic feet in the same quarter last year [5] - 'Gross Total Crude Oil Production' is projected at 410 thousand barrels, compared to 399 thousand barrels in the same quarter of the previous year [6] - 'Net Crude Oil and NGL Production per day - Kearl' is expected to be 173 thousand barrels, up from 167 thousand barrels year-over-year [7] - 'Net Crude Oil and NGL Production per day - Cold Lake' is estimated at 109 thousand barrels, consistent with the previous year's figure [8] - 'Gross Crude Oil and NGL Production per day - Syncrude' is projected at 79 thousand barrels, an increase from 66 thousand barrels year-over-year [9] - 'Total Refinery Throughput' is estimated at 393 thousand barrels, up from 387 thousand barrels in the same quarter last year [10] - 'Net Petroleum Products Sales' is expected to be 458 thousand barrels, down from 470 thousand barrels in the same quarter last year [11] Stock Performance - Over the past month, shares of Imperial Oil have returned +4.1%, outperforming the Zacks S&P 500 composite's +2.7% change [12] - Currently, Imperial Oil holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [12]

Core Insights - TransDigm Group (TDG) is expected to report quarterly earnings of $9.78 per share, reflecting an 8.7% increase year-over-year, with revenues projected at $2.3 billion, a 12.2% increase from the previous year [1] Earnings Estimates - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong correlation between earnings estimate revisions and short-term stock performance [2] - The consensus EPS estimate for the quarter has been adjusted upward by 0.7% over the past 30 days, indicating analysts' reassessment of projections [1] Key Metrics Projections - Analysts estimate 'Net sales to external customers- Non-aviation' at $47.46 million, a decrease of 3.2% year-over-year [4] - 'Net sales to external customers- Airframe' is projected at $1.06 billion, reflecting a 9% increase year-over-year [4] - 'Net sales to external customers- Power & Control' is expected to reach $1.20 billion, indicating a 17.1% year-over-year increase [5] - 'Net sales to external customers- Airframe- Commercial and non-aerospace OEM' is forecasted at $341.67 million, a 5.8% increase from the previous year [5] - 'Net sales to external customers- Airframe- Defense' is estimated at $317.24 million, showing a 4.7% increase year-over-year [6] - 'Net sales to external customers- Power & Control- Defense' is projected at $530.29 million, reflecting an 11.2% increase [6] - 'Net sales to external customers- Power & Control- Commercial and non-aerospace aftermarket' is expected to be $363.15 million, a 14.6% increase [7] - 'Net sales to external customers- Power & Control- Commercial and non-aerospace OEM' is forecasted at $250.82 million, indicating a 9.5% increase [7] - 'Net sales to external customers- Airframe- Commercial and non-aerospace aftermarket' is estimated at $392.46 million, a 12.8% increase [8] EBITDA Projections - Analysts predict 'EBITDA- Power & Control' to reach $670.36 million, up from $587.00 million in the same quarter last year [8] - 'EBITDA- Non-aviation' is expected to be $3.57 million, down from $22.00 million year-over-year [9] - 'EBITDA- Airframe' is projected at $550.98 million, compared to $503.00 million in the previous year [9] Stock Performance - Over the past month, TransDigm shares have returned +7.2%, outperforming the Zacks S&P 500 composite's +2.7% [10] - Currently, TDG holds a Zacks Rank 2 (Buy), suggesting potential outperformance in the near future [10]

Core Viewpoint - Analysts project that Pfizer will report quarterly earnings of $0.58 per share, reflecting a 3.3% decline year over year, with revenues expected to reach $13.78 billion, an increase of 3.7% from the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has been revised 0.2% lower over the last 30 days, indicating a collective reevaluation by analysts [2]. - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock price performance [3]. Revenue Projections - Analysts forecast 'Revenues- Oncology- Ibrance- Worldwide' to reach $1.05 billion, indicating a year-over-year decline of 6.9% [5]. - 'Revenues- Specialty Care- Xeljanz- Worldwide' is estimated at $219.35 million, reflecting a 27.6% decrease from the prior-year quarter [5]. - 'Revenues- Oncology- Xtandi alliance revenues- Worldwide' are expected to be $528.19 million, showing a year-over-year increase of 6.7% [6]. - 'Revenues- Specialty Care- Inflectra- Worldwide' is projected to reach $101.04 million, indicating a 4.2% increase year over year [6]. Regional Revenue Estimates - 'Revenues- Oncology- Ibrance- United States' is expected to be $702.67 million, reflecting a 5.2% decline year over year [7]. - 'Revenues- Specialty Care- Xeljanz- Total International' is estimated at $103.19 million, indicating a 15.4% decrease from the prior-year quarter [7]. - 'Revenues- Oncology- Ibrance- Total International' is projected to be $349.94 million, reflecting a 10.3% decline from the prior-year quarter [8]. - 'Revenues- Specialty Care- Xeljanz- United States' is expected to reach $116.16 million, indicating a significant year-over-year decline of 35.8% [8]. - 'Revenues- Oncology- Inlyta- Total International' is estimated at $89.23 million, reflecting an 11.7% decline from the prior-year quarter [9]. - 'Revenues- Oncology- Inlyta- United States' is projected to be $116.62 million, indicating a 22.8% decline year over year [9]. Primary Care Revenue Estimates - 'Revenue- Primary Care- Prevnar family- United States' is expected to be $826.39 million, reflecting a slight year-over-year decline of 0.7% [10]. - 'Revenue- Primary Care- Prevnar family- Total International' is projected to reach $536.11 million, indicating a 1.7% increase from the prior-year quarter [10]. Stock Performance - Pfizer shares have decreased by 6% in the past month, contrasting with the Zacks S&P 500 composite's increase of 2.7%, and the stock is expected to closely follow overall market performance in the near term [10].

Core Viewpoint - Analysts project that Masco (MAS) will report quarterly earnings of $1.08 per share, reflecting a 10% decline year over year, with revenues expected to reach $2 billion, down 4.1% from the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has been revised upward by 3.4% in the past 30 days, indicating a reassessment by covering analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock price performance [3]. Key Metrics - Analysts estimate 'Net Sales- Plumbing Products' to be $1.26 billion, representing a 0.5% increase year over year [5]. - The consensus for 'Net Sales- Decorative Architectural Products' is $744.34 million, indicating an 11.2% decline year over year [5]. - Expected 'Operating profit, as adjusted- Plumbing Products' is projected at $225.09 million, down from $249.00 million in the same quarter last year [6]. - Analysts forecast 'Operating profit, as adjusted- Decorative Architectural Products' at $145.41 million, compared to $174.00 million in the previous year [6]. - The projected 'Operating profit, as reported- Decorative Architectural Products' is $140.29 million, down from $174.00 million year over year [7]. - 'Operating profit, as reported- Plumbing Products' is expected to be $223.34 million, compared to $247.00 million in the same quarter last year [7]. Stock Performance - Over the past month, Masco shares have returned -0.7%, while the Zacks S&P 500 composite has changed by +3.4% [7]. - Masco holds a Zacks Rank 3 (Hold), suggesting its performance will likely align with the overall market in the upcoming period [7].

Core Insights - Simon Property (SPG) is expected to report quarterly earnings of $3.04 per share, reflecting a 4.8% increase year-over-year, with revenues projected at $1.51 billion, a 3.3% increase from the previous year [1]. Earnings Estimates - The consensus EPS estimate for the quarter has been revised upward by 0.2% over the past 30 days, indicating a collective reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock price performance [3]. Revenue Forecasts - Analysts estimate 'Revenue- Management fees and other revenues' to be $34.47 million, a year-over-year increase of 3.9% [5]. - 'Revenue- Lease income' is projected to reach $1.39 billion, indicating a 5.4% increase from the prior-year quarter [5]. - 'Revenue- Other income' is expected to be $94.02 million, reflecting a year-over-year decline of 14% [5]. Key Metrics - The consensus for 'U.S. Malls and Premium Outlets - Occupancy - Total Portfolio' is 96.0%, up from 95.6% in the same quarter last year [6]. - 'Depreciation and amortization' is forecasted to reach $326.23 million [6]. - Over the past month, shares of Simon Property have increased by 2.3%, compared to a 3.4% increase in the Zacks S&P 500 composite [6].

Halozyme Therapeutics (HALO) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on August 5, might help the stock move higher if these key numbers are better than ...

Group 1 - Omnicom's shares have increased by 3.7% over the past four weeks, closing at $74.63, with a mean price target of $93.56 indicating a potential upside of 25.4% [1] - The mean estimate consists of nine short-term price targets with a standard deviation of $13.43, where the lowest estimate is $78.00 (4.5% increase) and the highest is $116.00 (55.4% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [11][12] Group 2 - The Zacks Consensus Estimate for the current year has increased by 1.7%, with four estimates moving higher and no negative revisions in the last 30 days [12] - Omnicom holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the extent of gains, it suggests a positive direction for price movement [14]